ESMO 2023

Preoperative checkpointinihition in ER+ disease

Highlights in eBC

5 year follow-up

Remarkable efficacies in patients with HER2+ mBC with…

DATO-DX - where is it going?

Lu-PSMA leads forward

When the history of ADC is written: Redefining…

The FGFR story in bladder cancer at ESMO23

New 3rd line therapy for RCC

Clearing up non-clear cell RCC

Amivantamab as a new SoC for EGFR Exon 20…

ALINA - immediate change of practice!

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Tarlatamab in SCLC

Perioperativ immunotherapy for all resectable stage…

Data updates for CDK4/6 inhibitors in EBC at ESMO23 -…

New and better biomarkers are needed!

Anticipated updates and exciting new data for…

What was the most exciting news at ESMO23?

Prognostic score in early HR+/HER2-BC: translational…

Analysis of tumour microenvironment and…

Consolidation of data in early HR+ and triple-negative…

My highlights of ESMO23 in early breast cancer

HR+ study with > 20 % PCR

Neoadjuvant IO - is their new strategy in HR+ breast…

ER-low corresponds diagnostically to ER-0 breast cancer

Immunoncology in eBC - triple negative and more?

Our guidelines are correct

New data on neoadjuvant immunotherapy

MonarchE - trial update

Negative EFS results from NeoTrip

5 year follow-up

Pembrolizumab solidifies as SOC in early-stage TNBC

Preoperative checkpointinihition in ER+ disease

Metabolomics reveal differential expression of OMEGA 3…

Use of immunotherapy in the perioperative setting of…

Clinically relevant effect of pembro also in PCR

Carry-over effects in monarchE confirmed

Ribociclib effective in all subtypes

Detailed view of nodal-negative patients

MonarchE - mise à jour de l'essai

Nouvelles données sur l'immunothérapie néoadjuvante

Studio NeoTrip: negativi i risultati

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6…

ADCs in HER2+, HER2low and TNBC - what is the future of…

New targets, new linker, new ADCs - much more to learn…

Improvement of therapy outcome by app-based patient…

What was the most exciting news at ESMO23?

New ADC for metastatic breast cancer?

Patient-centered molecular medicine - a new approach

OP-1250 (Palezestrant) confirms the role of SIRDs after…

New ADC in HR+ disease

Even more new generation ADCs in breast cancer?

Highlights in mBC

Fulvestran better than anastrozole, but no survival…

TROP2 expression as a potential mechanism of resistance…

Still on track for success in HER2-low MBC

DATO-DX - where is it going?

ADC + Immunotherapy - the BEGONIA study paradigm

Abemaciclib remains consistent in 5-year follow-up

My highlights of ESMO23 in metastatic breast cancer

T-DXd also effective for brain metastases

Benefit for SG even after intensive pretreatment

Dato-DXd - new player in advanced luminal disease

Can surgery be spared following primary systemic…

OP seems to be dispensable for super responders

Improved oncological therapy with the smartphone

T-DXd - new standard of care for brain mets?

Duvalumab + Dato-DXd effective

Remarkable efficacies in patients with HER2+ mBC with…

Robust data from the monarchE

HS20089 - a novel ADC is coming for TNBC

HER2DX in the PHERgain trial

T-DXd in HER2+ patients with brain metastases

TULIP: Trastuzumab duocarmazine without OS benefit

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym…

La expresión de TROP2 como potencial mecanismo de…

Punti salienti in mBC

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par…

T-DXd - nowy standard postępowania w przerzutach do…

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei…

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

Lo studio BEGONIA nelle paziento con tumore triplo…

HER2DX en el estudio PHERgain

Should we use zoledronic acid in all ADT patients?

The optimal timing of RT after radical prostatectomy…

What is the future of immune therapy in prostate…

ENZA P:Trial and controversies

Early use of enzalutamide in advanced prostate cancer

EMBARK - Quality of Life

Salvage radiotherapy the new standard

PSMA FORE: Trial and controversies

Embark without fear

Precision medicine at mCRCP

Negative data for pembrolizumab in mHSCPC & mCRPC

Immunotherapy in metastatic PCa

Osteoprotection at mHSPC

PSMAfore unleashes urooncologic opportunity

TITAN: ultra-low PSA = best prognosis

Longterm toxicity of adjuvant RT after prostatectomy

Brave New World in mCRPC

CXCR2 inhibitor in PCa

Combination of radioligand therapy with chemotherapy…

IO therapy in metastatic prostate cancer.

STAMPEDE. Bone prediction not for everyone - better…

RADICALS RT: Trial and controversies

Big data and AI prediction tools

Lu-PSMA leads forward

EMBARK expands ENZA indication to PCa

Immunterapi vid prostatacancer

EMBARK och livskvalitet

Big Data och AI för prediktion vid prostatacancer

Cuando la inmunoterapia probablemente no es la mejor…

CXCR2 hämmare och prostatacancer

Part 2: New standard of care in first line urothelial…

Part1: New standard of care in first line urothelial…

EV + Pembro as standard of care in first-line therapy…

DAD, DAD-IO

When the history of ADC is written: Redefining…

The FGFR story in bladder cancer at ESMO23

FGFR inhibitors: What is the best scenario for this…

Amazing new data in bladder cancer

Unique bladder delivery system of gemcitabine herolds…

New SoC in firstline bladder cancer

Reescribiendo la historia de una enfermedad: Nuevo…

Inhibidores de FGFR: Cual es el mejor escenario para…

L'histoire du FGFR dans le cancer de la vessie à…

Is de-escalating therapy ready for prime-time?

Important new treatment option but only for subset of…

Kidney cancer highlights at ESMO23

Belzutifan in later lines of therapy

New mode of action in mRCC - ready for prime time?

Belzutifan - whats next kidney cancer?

Clearing up non-clear cell RCC

New 3rd line therapy for RCC

ALINA - remarkably positive DFS in early-stage ALK+…

Perioperative IO: OS-benefi from KEYNOTE-671

My highlights from ESMO 2023

Scene is set for inductive immunotherapy

Big improvements in early stage and a subset of…

Adjuvant alectinib in patients with early-stage ALK+…

Neoadjuvant chemo-immunotherapy new standards in early…

ALINA - a new paradigm in operated NSCLC with…

Substantial improvement in local regional NSCLC

Perioperativ immunotherapy for all resectable stage…

Circulating DNA in AEGEAN trial

I miei punti salienti di ESMO 2023

Perioperatieve chemo-immunotherapie voor alle patienten…

Les points forts de l'ESMO 2023

Gros progrès dans les traitments medicaeux des stades…

Evolving landscape of ADCs

Rare oncogenic alterations: landmark results on exon 20…

ESMO2023-impact on everyday practice!

Amivantamab at progression? MARIPOSA-2 trial

Treatment sequences for EGFR-mutated Patients

LIBRETO - a positive study, but was it necessary?

PAPILLON - bringing together therapy for the 1st line

Amivantamab as a new SoC for EGFR Exon 20…

NRG fusions: a new drugable target?

Practice changing results on exon 20 insertion mNSCLC

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Changing treatment landscape in EGFR-mutated NSCLC

MARIPOSA II: Trial and controversies

Do ADCs have brain activity?

My highlights from ESMO 2023

Does immunotherapy still have a place in EGFR-positive…

Adagrasib + pembrolizumab in patients with KRASG12C…

Brain metastases – options to improve the systemic…

Big improvements in early stage and a subset of…

Amivantamab upfront? MARIPOSA trial

TROPION-Lung01: positive development

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

Substantial improvement in rare alterations

New standard of care for metastatic EGFR exon 20…

By unanimous decision and still the champion –…

Les points forts de l'ESMO 2023

Quelles séquences thérapeutiques pour les patients EGFR…

Gros progrès dans les traitments medicaeux des stades…

Heeft immunotherapie nog een plek in de behandeling van…

I miei punti salienti di ESMO 2023

Nieuwe standaard voor gemetastaseerd EGFR exon20…

Amivantamab at progression? MARIPOSA-2 trial

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Veränderte Behandlungslandschaft bei EGFR-mutiertem…

Amivantamab upfront? MARIPOSA trial

New hope for patients with SCLC

Tarlatamab in SCLC

First data on luveltamab in multiline treatment for…

Precision oncology in CUP

Update on gynaecological cancers

Evolution of the revolution - the RUBY trial

New data on sarkomas

PCO Therapeutics